<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
<PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
        <PMID Version="1">26148604</PMID>
        <DateCompleted>
            <Year>2016</Year>
            <Month>03</Month>
            <Day>31</Day>
        </DateCompleted>
        <DateRevised>
            <Year>2015</Year>
            <Month>07</Month>
            <Day>07</Day>
        </DateRevised>
        <Article PubModel="Print">
            <Journal>
                <ISSN IssnType="Electronic">1998-4138</ISSN>
                <JournalIssue CitedMedium="Internet">
                    <Volume>11</Volume>
                    <Issue>2</Issue>
                    <PubDate>
                        <MedlineDate>2015 Apr-Jun</MedlineDate>
                    </PubDate>
                </JournalIssue>
                <Title>Journal of cancer research and therapeutics</Title>
                <ISOAbbreviation>J Cancer Res Ther</ISOAbbreviation>
            </Journal>
            <ArticleTitle>Prospective study of special stage II (T2b-3N0M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy.</ArticleTitle>
            <Pagination>
                <MedlinePgn>381-7</MedlinePgn>
            </Pagination>
            <ELocationID EIdType="doi" ValidYN="Y">10.4103/0973-1482.157332</ELocationID>
            <Abstract>
                <AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">To analyze the effects of hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy (Hypo-SIB-IMRT) on medically inoperable patients with special stage II (T2b-3N0M0) non-smallcell lung cancer (NSCLC).</AbstractText>
                <AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Twenty-eight qualified patients were included. Hypo-SIB-IMRT was delivered with internal gross tumor volume (iGTV) 75 Gy, clinical target volume (CTV) 60 Gy, and planning target volume (PTV) 45 Gy on weekdays in 3 weeks.</AbstractText>
                <AbstractText Label="RESULTS" NlmCategory="RESULTS">The 1-, 2-, and 3-year overall survivals (OSs) were 93, 85, and 61%, respectively, with a median survival of 46.5 months; while progression-free survivals (PFSs) were 92, 79, and 64%; and distant metastasis-free survivals (DMFSs) were 92, 84, and 77%, respectively. The cancer-specific survivals (CSS) were 93, 88, and 74%, and local control (LC) were 92, 83, and 74%, respectively. 7.1% (2/28) of patients occurred local pain, 28.6% (8/28) were with Grade 1 or 2 radiation pneumonitis (RP), and 7.1% (2/28) with Grade 1 esophagitis. Of the eight patients with RP, 17.9% (5/28) developed Grade 1 radiation pulmonary fibrosis (RPF).</AbstractText>
                <AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">Due to the favorable long-term survivals, LC, and minimal toxicities, Hypo-SIB-IMRT presented in this prospective study may be considered an option for patients with special stage II (T2b-3N0M0) NSCLC who were medically inoperable.</AbstractText>
            </Abstract>
            <AuthorList CompleteYN="Y">
                <Author ValidYN="Y">
                    <LastName>Zhang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Liu</LastName>
                    <ForeName>Chengxin</ForeName>
                    <Initials>C</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Lin</LastName>
                    <ForeName>Haiqun</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Song</LastName>
                    <ForeName>Yipeng</ForeName>
                    <Initials>Y</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Huang</LastName>
                    <ForeName>Wei</ForeName>
                    <Initials>W</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Hongsheng</ForeName>
                    <Initials>H</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Miaomiao</ForeName>
                    <Initials>M</Initials>
                </Author>
                <Author ValidYN="Y">
                    <LastName>Li</LastName>
                    <ForeName>Baosheng</ForeName>
                    <Initials>B</Initials>
                    <AffiliationInfo>
                        <Affiliation>Department of Radiation Oncology VI, Shandong Cancer Hospital, 440 Jiyan Road, Huaiyin Area, Jinan, Shandong province, China.</Affiliation>
                    </AffiliationInfo>
                </Author>
            </AuthorList>
            <Language>eng</Language>
            <PublicationTypeList>
                <PublicationType UI="D016428">Journal Article</PublicationType>
                <PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType>
            </PublicationTypeList>
        </Article>
        <MedlineJournalInfo>
            <Country>India</Country>
            <MedlineTA>J Cancer Res Ther</MedlineTA>
            <NlmUniqueID>101249598</NlmUniqueID>
            <ISSNLinking>1998-4138</ISSNLinking>
        </MedlineJournalInfo>
        <CitationSubset>IM</CitationSubset>
        <MeshHeadingList>
            <MeshHeading>
                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D002289" MajorTopicYN="N">Carcinoma, Non-Small-Cell Lung</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008175" MajorTopicYN="N">Lung Neoplasms</DescriptorName>
                <QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName>
                <QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011832" MajorTopicYN="N">Radiation Injuries</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D017564" MajorTopicYN="N">Radiation Pneumonitis</DescriptorName>
                <QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011879" MajorTopicYN="N">Radiotherapy Dosage</DescriptorName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D011880" MajorTopicYN="N">Radiotherapy Planning, Computer-Assisted</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
            <MeshHeading>
                <DescriptorName UI="D050397" MajorTopicYN="N">Radiotherapy, Intensity-Modulated</DescriptorName>
                <QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName>
                <QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
            </MeshHeading>
        </MeshHeadingList>
    </MedlineCitation>
    <PubmedData>
        <History>
            <PubMedPubDate PubStatus="entrez">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="pubmed">
                <Year>2015</Year>
                <Month>7</Month>
                <Day>8</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
            <PubMedPubDate PubStatus="medline">
                <Year>2016</Year>
                <Month>4</Month>
                <Day>1</Day>
                <Hour>6</Hour>
                <Minute>0</Minute>
            </PubMedPubDate>
        </History>
        <PublicationStatus>ppublish</PublicationStatus>
        <ArticleIdList>
            <ArticleId IdType="pubmed">26148604</ArticleId>
            <ArticleId IdType="pii">JCanResTher_2015_11_2_381_157332</ArticleId>
            <ArticleId IdType="doi">10.4103/0973-1482.157332</ArticleId>
        </ArticleIdList>
    </PubmedData>
</PubmedArticle>

</PubmedArticleSet>